 
 
The Practical Anemia Bundle for Sustained 
Blood Recovery (PABST -BR) in Critical Illness 
Randomized Clinical Trial  
 
NCT# 05167734  
 
11October2022  
   
 The Practical Anemia Bundle for Sus tained Blood Recovery 
(PABST -BR) in Critical Illness Randomized Clinical Trial  
 
Protocol Number : IRB #  21-006511  
National Clinical Trial (NCT) Identified Number:  < TBD> 
 
Principal Investigator:  [INVESTIGATOR_40613] A. Warner, MD  
Funded by : [CONTACT_411634]: 5.0 
11 October  2022  
 
 
Initial version : 5 October  2021, Version 1.0  
Revised:  28 March 2022, Version 2.0   
Revised:  11 May 2022, Version 3.0   
Revised:  26 July 2022, Version 4.0   
Revised:  [ADDRESS_519090]. Matthew Warner   CONFIDENTIAL  
 ii Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  1 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  1 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  1 
1.2 Schema  ................................ ................................ ................................ ................................ .................  3 
1.3 Schedule of Activities (SoA)  ................................ ................................ ................................ ...............  4 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  4 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .... 4 
2.2 Background ................................ ................................ ................................ ................................ ...........  5 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ....................  7 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ..... 7 
2.3.2  Known Potential Benefits  ................................ ................................ ................................  8 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ................................  8 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ..............  10 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ ...........  11 
4.1 Overall Design  ................................ ................................ ................................ ................................ .... 11 
4.2 Scientific Rationale for Study Design ................................ ................................ ..............................  13 
4.3 Justification for Dose  ................................ ................................ ................................ .........................  13 
4.4 End of Study Definition  ................................ ................................ ................................ .....................  13 
5 STUDY POPULATION  ................................ ................................ ................................ ................................  13 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................  13 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...............................  14 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ....................  14 
5.4 Screen Failures  ................................ ................................ ................................ ................................ .. 14 
5.5 Strategies for Recruitment and RetentioN  ................................ ................................ .....................  15 
6 STUDY INTERVENTION  ................................ ................................ ................................ ............................  16 
6.1 Study Intervention(s) Administration  ................................ ................................ ...............................  16 
6.1.1  Study Intervention Description  ................................ ................................ .....................  16 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ................  [ADDRESS_519091] Storage and Stability  ................................ ................................ .......................  17 
6.2.4  Preparation  ................................ ................................ ................................ ......................  18 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ...........................  18 
6.4 Study Intervention Compliance  ................................ ................................ ................................ ........  18 
6.5 Concomitant Therapy  ................................ ................................ ................................ ........................  18 
6.5.1  Rescue Medicine  ................................ ................................ ................................ ............  18 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL.  ................................ ................................ ................................ ...................  18 
7.1 Discontinuation of Study Intervention  ................................ ................................ .............................  18 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  [ADDRESS_519092] to Follow -Up ................................ ................................ ................................ ...............................  19 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ .....................  19 
8.1 Efficacy Assessments  ................................ ................................ ................................ .......................  19 
8.2 Safety and Other Assessments  ................................ ................................ ................................ .......  20 
8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  20 
8.3.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  20 
8.3.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  [ADDRESS_519093]  ................................ ................................ .............................  23 
8.3.9  Reporting of Pregnancy  ................................ ................................ ................................  23 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  23 
8.4.1  Definition of Unanticipated Problems (UP)  ................................ ................................ . 23 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ................  23 
8.4.3  Reporting Unanticipated Problems to Participants  ................................ ...................  24 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  24 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  24 
9.2 Sample Size Determination  ................................ ................................ ................................ ..............  24 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  24 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  25 
9.4.1  General Approach  ................................ ................................ ................................ ..........  25 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ................................ .............................  25 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ .......  [ADDRESS_519094]. Matthew Warner   CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical Practice ( ICH 
GCP) and the following :  
 
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 
CFR Part 56, 21 CFR Part 312 , and/or 21 CFR Part 8 12)  
 
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who are responsible  for the conduct, 
management, or  oversight of NIH -funded clinical trials  have completed Human Subjects Protection and ICH GCP 
Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the 
Institutional Review Board ( IRB) for review and approval.  Approval of both the protocol and the consent form must be 
obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by [CONTACT_242206].  In addition, a ll changes to the consent form will be IRB -approved; a 
determination will be made regarding whether  a new consent needs to be obtained from participants  who provided 
consent , using a previously approved consent form . 
 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS   
Title:  The Practical Anemia Bundle for SusTained Blood Recovery (PABST -BR) in Critical Illness 
Randomized Clinical Trial  
Study Des cription : The goal of this investigation is to test a multi -faceted anemia prevention and targeted 
treatment bundle (optimized phlebotomy, decision support, targeted pharmacologic 
treatment) to attenuate anemia development and promote hemoglobin and functional 
recovery in adults with critical illness.  We hypothesize that the bundle will improve 
hemoglobin recovery and functional outcomes through [ADDRESS_519095] -hospi[INVESTIGATOR_059].    
Objectives:  
 Primary Objective :  To assess the efficacy  of the intervention on mean difference in 
hemoglobin concentrations at 1 month after hospi[INVESTIGATOR_059].  
 Secondary Objectives:   
To assess the impact of the intervention on:  
• hemoglobin concentrations through [ADDRESS_519096] hospi[INVESTIGATOR_059]  
• functional outcomes (Core Outcome Measurement Set [COMS], PROMIS -FATIGUE) 
at [ADDRESS_519097] -hospi[INVESTIGATOR_059]  
• RBC transfusions through [ADDRESS_519098] -hospi[INVESTIGATOR_059]  
• hospi[INVESTIGATOR_411582] [ADDRESS_519099] -hospi[INVESTIGATOR_059]  
• mortality through [ADDRESS_519100] -hospi[INVESTIGATOR_411583] s: Prim ary Endpoint:  Hemoglobin concentrations (m ean difference in hemoglobin 
concentrations at 1-month  post -hospi[INVESTIGATOR_059])  
Secondary Endpoints:  
• Hemoglobin concentrations ( through [ADDRESS_519101] -hospi[INVESTIGATOR_059])  
• Functional outcomes ( EQ-5D, PROMIS -FATIGUE , 6-minute walk distance, daily step 
counts and energy expenditure, activities of daily living survey, MOCA -BLIND , HADS, 
IES-R) at 1 and 3 -months postop -hospi[INVESTIGATOR_059]  
• RBC transfusions  through [ADDRESS_519102]. Matthew Warner   CONFIDENTIAL  
 • Readmissions in first [ADDRESS_519103] -hospi[INVESTIGATOR_059]  
• All-cause mortality through [ADDRESS_519104] -hospi[INVESTIGATOR_411584]:  100 patients, male and females, age > 18 years, moderate -to-severe comorbid illness 
burden, moderate -to-severe acute illness burden, in ICUs at Mayo Clinic  [COMPANY_002]ster  
Phase:  2   
Description of 
Sites /Facilities  Enrolling 
Participants : ICUs at Mayo Clinic [COMPANY_002]ster, MN ; a large tertiary care academic medical center    
Description of Study  
Intervention : Participants will be randomized 1:[ADDRESS_519105] of care using a 
stratified permuted block design by [CONTACT_411635] (iron -responsive vs. inflammatory) and ICU 
admission indication (surgical vs. non -surgical).   
 
The intervention arm is multi -faceted with 3 primary components:  
1) Optimized phlebotomy , defined by : 
• minimal volume draws  
• closed -loop blood sampling  
• bundling of similarly timed  labs, all performed by a dedicated phlebotomy team 
independent from the treatment team  
 
2) Decision support aids , including : 
• visual and electronic alerts reminding the care team to minimize non -essential 
laboratory testing , mitigate patient -specific bleeding risk  
• daily communication with the ICU care team during clinical rounds to reiterate the 
purpose of the study  
 
3) Pharmacologic  anemia treatment (given immediately  following randomization) targeted 
to [ADDRESS_519106] groups:  
1) Anemia responsive to iron supplementation (i.e. 1000 mg IV low molecular 
weight iron dextran), and  
2) Anemia  of inflammation  requiring erythropoietic stimulation (i.e. 40,000 units of 
subcutaneous erythropoietin  +/- iron supplementation as needed to augment iron 
stores prior to EPO dosing )   
Study Duration:  2 years  
Participa nt Duration:  [ADDRESS_519107] -discharge  
  Screen potential participants by [CONTACT_156587]/exclusion criteria.  
Obtain informed consent  of 100 participants.  
Administer initial study intervention:  
• Optimized phlebotomy. Place card on patient door.  
• Clinical Support/Rounding checklist to ICU care team  
• 1000 mg IV iron  or 40,000 units subcutaneous EPO  or both  
• Perform baseline assessments (refer to Section 1.3 SOA)  
 
 
Follow -up assessment s of study endpoints and safety  
(refer to Section 1.3 SOA)  
• Hemoglobin and iron studies  
• Functional outcome assessments  • Review Clinical Support Card/Rounding Checklist with ICU team.  
• Ensure Optimized Phlebotomy card in place  
• Document AE’s , labs, daily RBC transfusions, daily fluid balance  
Final Assessments  
(refer to Section 1.3 SOA)   
Intervention Arm  
50 participants  Control Arm  
50 participants  Randomize  
• Schedule follow -up appointments  
• Complete EQ -5D, PROMIS FATIGUE, and Fatigue Assessment  
• Record hemoglobin, iron study results  Perform baseline 
assessments 
(refer to Section 
1.3 SOA)  
 
 
Document AE’s, labs, 
daily RBC transfusions , 
daily fluid balance  
 
 
EMR review  only  
• All cause mortality  
• Hospi[INVESTIGATOR_411585] -BR                             Version 5.[ADDRESS_519108]. Matthew Warner   CONFIDENTIAL  
 1.3 SCHEDULE OF ACTIVITIES (SOA)  
Procedures  Enrollment/
Baseline 
Study day [ADDRESS_519109] -
hospi[INVESTIGATOR_059] 
+/- [ADDRESS_519110] -
hospi[INVESTIGATOR_059] 
+/- [ADDRESS_519111] -
hospi[INVESTIGATOR_411586]  X      
Demographics  X      
Medical history  X      
Randomization  X      
Administer study intervention  X      
Vital signs - (BP, HR, RR, O2 sat)  X      
Height  X      
Weight  X  X    
Pregnancy test if needed  X      
Anemia labsa X X X X X  
Platelet countd X  X    
White blood cell countd X  X    
Creatinined X  X    
Functional outcome  assessment  b X  X X X  
Con medication review  c X X     
Fluid balance X  X    
RBC transfusions documented  X X X X X  
Daily phlebotomies for labs 
(excluding RMGs)   X X    
Fatigue assessment    X X X  
AE review and evaluation  X X X X X  
Research Samplese X   X X  
Hospi[INVESTIGATOR_411587]     X X X 
All cause mortality status       X 
Complete Case Report Forms  X X X X X X 
a. Hemoglobin , ferritin , and  transferrin saturation will be obtained for all patients at enrollment, hospi[INVESTIGATOR_47850], [ADDRESS_519112] -hospi[INVESTIGATOR_059] . 
Other anemia labs to be reported at these and other timepoints include, if available Hemoglobin, MCV, RDW, ferritin, iron, transferrin saturation, reticulocyte 
hemoglobin, absolute reticulocyte count; record all values available  recognizing that not all non -hemoglobin values will be available at each interval.  
b. Functional outcomes according to the Core Outcome Measurement Set will be obtained in the following fashion:  Enrollment  – ADL survey (by [CONTACT_411636]); 
at Hospi[INVESTIGATOR_2345]  – EQ-5D, PROMIS -FATIGUE; at 1-month and 3 -months  – EQ-5D, PROMIS -FATIGUE, 6MWD, ADL Survey, MoCA -BLIND, HADS, IES -R, activity 
monitoring (optional study component) .  
c. Concomitant meds review to include y/n for antiplatelet agents (i.e.  aspi[INVESTIGATOR_248], clopi[INVESTIGATOR_7745]), anticoagulants (i.e. heparin, warfarin, direct oral anticoagulants, low 
molecular weight heparins), iron, and erythropoiesis stimulating agent use  (i.e. darbepoetin, EPO). Daily visits only need to report if they received iron or 
EPO/darbepoetin.  
d. Platelets, WBC and Creatinine will be collected if done as standard of care. Baseline results used should be from within [ADDRESS_519113] to discharge up to 72 hours prior.  
e. Research samples (10 ml phlebotomy) will be  obtained at enrollment, 1 -month, and 3 -months  and stored for potential biomarker assessment (i.e. hepcidin, IL -6, 
C-reactive protein) for future mechanistic studies on anemia development and recovery in critical illness survivors.  
 
[ADDRESS_519114] a multi -faceted anemia prevention and targeted 
treatment bundle (optimized phlebotomy practice, decision support, targeted pharmacologic anemia treatment) to 
attenuate anemia development and promote hemo globin and functional recovery in the setting of critical illness. 
Specifically, we aim to assess the impact of the intervention on hemoglobin concentrations and functional outcomes (i.e.  
physical, cognitive, mental health) through 3 -months after hospi[INVESTIGATOR_059].   
 
2.2 BACKGROUND   
Anemia is remarkably common in the critically ill.1–[ADDRESS_519115] become more tolerant of 
anemia during hospi[INVESTIGATOR_411588], a phenomenon driven in large part by [CONTACT_411637] (TRICC) trial,4 which revealed similar 30 -day mortality with restrictive versus liberal red 
blood cell (RBC) transfusion strategies. However, we now realize that survival of critical illness does not guarantee the 
quality of the life preserved. Up to 50% of survivors have substantial functional deficits in one or multiple domains 
related to physical function, cognition, mental health, and quality of life.5 This is increasingly relevant given the growing 
number of survivors of COVID -19-related critical illness.6 It is therefore paramount that we identify modifiable risk 
factors for impaired functional recovery in ICU survivors, of which anemia may be one potential target.7 Importantly, 
anemia has consistently been linked with impaired functional outcomes in non -critically ill populations, including the 
elderly,8–[ADDRESS_519116] -surgical patients,12–[ADDRESS_519117] -hospi[INVESTIGATOR_411589], a prospective investigation of  19 critically ill patients with 
anemia discovered that approximately 50% remained anemic 6 -months later.20 In our data from 6460 survivors of critical 
illness enrolled in  large population -based health study,21,22 80% of subjects were discharged from the hospi[INVESTIGATOR_411590].[ADDRESS_519118] -hospi[INVESTIGATOR_059], only half of those alive with available hemoglobin assessments had 
recovered to non -anemic status, with recovery varying in accordance with anemia severity at hospi[INVESTIGATOR_2345]. These 
data confirm that for many patient’s  anemia persists long after the resolution of critical illness. Additionally, higher 
hemoglobin concentrations at hospi[INVESTIGATOR_411591] -hospi[INVESTIGATOR_411592] (HR 0.95 [95% CI 0.90 -0.99], per 1 g/dL i ncrease; p=0.020), suggesting that anemia may have 
important implications for downstream clinical outcomes.  Preliminary data from this cohort also shows that hemoglobin 
concentrations are strongly associated with unplanned hospi[INVESTIGATOR_411593] 30 -days after hospi[INVESTIGATOR_7954], with each 1 g/dL increase in hemoglobin associated with a 15% reduction in the instantaneous hazard for 
readmission  after multivariable adjustmen t (HR 0.85, 95% CI 0.78, 0.93; p< 0.001; unpublished) . Patient readmission 
status over time by [CONTACT_411638][INVESTIGATOR_411594] 1.   
 
Protocol PABST -BR                             Version 5.[ADDRESS_519119]. Matthew Warner   CONFIDENTIAL  
  
While the relationships between anemia and functional recovery after critical illness remain incompletely defined, 
our recent data from a multi -center prospective cohort of 195 survivors of acute respi[INVESTIGATOR_411595] d physical function 3 -months later,7 including 
reductions in ambulatory capacity (i.e. 6 -minute walk distance [6MWD]) and activities of daily living (ADLs). This suggests 
that anemia may represent a modifiable risk factor for improved physical outcomes after critical illness.  However, 
relationships with other functional outcomes (cognition, mental health, quality of life) remain unknown, and it is unclear 
what effect the extent and timing of recovery from anemia after critical illness may have on outcomes.  These 
multidimensional functional ou tcomes have been deemed of the highest importance for contemporary critical illness 
research.[ADDRESS_519120] prominently, this includes the use of low -volume blood sampling strategies.  Observational suggests 
that these low -volume blood draw strategies may decrease iatrogenic blood loss and transfusions ,24 though clinical trial 
data is limited.25,26 In addition to low -volume phlebotomy, the use of clinical decision support is another method to 
promote appropriate lab utilization and to minimize excessive blood draws , though this has not been formally studied in 
critically ill patients. Regarding  non-transfusion -based  anemia treatment options, iron and erythropoietin (EPO) have 
been used in numerous clinical trials in  the setting of  critical illness .27–[ADDRESS_519121] -hospi[INVESTIGATOR_82814].  However, patients receiving the treatment had a significant reduction in 
90-day mo rtality (17% vs. 8%). Additionally, there is growing evidence in surgical patients that anemia treatment can 
have positive consequences for patients that extend beyond hospi[INVESTIGATOR_059].[ADDRESS_519122] -hospi[INVESTIGATOR_411596].  
Each patient random ized to the intervention will receive 3 treatment components: 1) optimized phlebotomy practice; 2) 
clinical decision support; and 3) pharmacologic anemia treatment.  With regards to pharmacologic anemia treatment, 
patients may receive either a single dose of intravenous (IV) iron therapy in isolation if they have an iron -responsive 
anemia or a single dose of EPO if they have an anemia of inflammation requiring erythropoietic stimulation.  Further, 
some patients receiving EPO may also receive a single dose o f IV iron to replenish iron stores prior to EPO administration  
Figure 1 . The percentage of patients 
still alive and not readmitted to the 
hospi[INVESTIGATOR_307] (y -axis) over time (x -axis) is 
shown for critical illness survivors 
without anemia (hemoglobin >12 g/dL 
females, >13 g/dL males)  and with 
mild (hemoglobin 10 -12 g/dL female, 
10-13 g/dL male), mode rate 
(hemog lobin 8-10 g/dL), and severe 
anemia (hemoglobin < 8 g/dl) at 
hospi[INVESTIGATOR_2345].  
 
Protocol PABST -BR                             Version 5.[ADDRESS_519123]. Matthew Warner   CONFIDENTIAL  
 (i.e. if serum ferritin is < 1000 ng/ml at the time of randomization).  Patients randomized to the standard of care arm will 
receive usual ICU cares.   
 
2.3 RISK/BENEFIT ASSESSMENT    
 
2.3.1  KNOWN  POTENTIAL RISKS  
There is minimal patient risk associated with the employment of 1) optimized phlebotomy practices, or 2) decision -
support aids.  Changes to phlebotomy practice include: default low -volume blood sampling (e.g. 0.[ADDRESS_519124] lab 
draws rather than 3 -10 ml ), which exposes the patient to no direct risk, and utilization of closed -loop blood sampling 
systems in order to minimize blood draw waste, again with no direct risk to the patient.  Low -volume blood sampling is 
already used clinically in our ICU environm ents for patients with severe anemia. In rare circumstances (<1%), a low -
volume sample may be insufficient for laboratory testing and additional phlebotomy may be required. Closed -loop blood 
sampling for those with pre -existing arterial or central venous c atheters provides a method of returning “waste blood” 
directly to the patient rather than disposing of this “waste” volume, which typi[INVESTIGATOR_411597] [ADDRESS_519125]. At 1 and 3 -month  follow -up, patients will again undergo 
phlebotomy testing. There is a risk of patient discomfort with the additional blood draws at these follow -up 
assessments, which will be disclosed at the time of enrollment. Patients will retain the right to refuse th ese blood draws 
or any other follow -up measures. Additionally, a total of 5cc of blood will be removed for laboratory sampling at each 
follow -up assessment; this is not expected to have any substantial negative clinical consequence.  
 
The third component of the clinical intervention is the utilization of EPO and/or  iron for the treatment of anemia, which 
does carry tangible patient risk s. Iron will be administered as a single 1000 mg dose of IV low molecular -weight iron 
dextran . This is  an approved therapy for patients with iron -deficiency anemia that is utilized in current clinical practice 
for critically ill patients with anemia and contraindications to transfusion therapi[INVESTIGATOR_014] (i.e. Jehovah’s witness patients) and 
post -surgical patients after large volume blood loss. The estimated incidence of SAEs with newer IV iron formulations, 
such as low molecular weight iron dextran, is less than 1 in 250,000 administrations.34 Nevertheless, immediate risks of 
IV iron are real and include allergic reactions (<1%) and non -allergic infusions reactions (e.g. myalgias, arthralgias, 
dizziness, <1%). Additionally, as a long -term risk, repeated doses of iron administration, particularly to patients with iron 
storage disorders (i.e. hemochromatosis) or those requiring frequent and recurrent RBC transfusions, can culminate in 
iron overload. Patients with hemochromatosis or elevated iron stores (i.e. ferritin > 1000 ng/ml) will not be elig ible to 
receive iron therapi[INVESTIGATOR_411598].  
 
EPO  (i.e. Epoetin alpha) , the  erythropoiesis stimulating  agent utilized in this trial, will be administered as a single 40,000 
unit subcutaneous injection  after iron supplementation , though iron supplementation will be withheld for those with 
ferritin > 1000 ng/ ml.  It has been used in previous clinical trials of anemia management in critical illness, and it is 
utilized in our current clinical practice for critically ill anemic and post -surgical patients with contraindications to 
transfusion therapi[INVESTIGATOR_014] (i.e. Jehovah’s witness patients). There are short -term risks associated with this therapy, including 
minor non -allergic adverse reactions (nausea, dizziness, high blood pressure, prurit is; estimated <10%) and major rare 
adverse reactions (e.g. deep venous thrombosis, uncontrolled hypertension, myocardial infarction; estimated <1%). 
There is a black box warning for myocardial infarction, stroke, venous thromboembolism, vascular access thr ombosis, 
and mortality when targeting hemoglobin levels >11 g/dL, data which is derived from repeated  use of EPO to achieve 
near -normal hemoglobin levels for patients with chronic kidney disease. In a recent systematic review and meta -analysis 
of 21 trials in critical illness, the relative risk (RR) for mortality with EPO was 0.82 (95% CI 0.71 -0.94).35 There were no 
significant differences in serious adverse events (RR 1.11, 95% CI 0.94 -1.31) or VTE (RR 1.17, 95% CI 0.87 -1.58), though 
these data do not exclude the potential for a clinically significant increase in the risk for adverse events with EPO 
therapy. As a longer -term risk, EPO may theoretically increase the risk of tumor progression or recurrence in patients 
with cancer . However,  these concerns are derived from trials in non -surgical oncologic patients utilizing large doses of 
ESAs for extended periods of time, particularly when targeting normal hemoglobin levels.36–[ADDRESS_519126]. Matthew Warner   CONFIDENTIAL  
 alone; hence, the potential benefits of IV iron in this group are high while the potential harms of EPO administration 
(e.g. thrombosis) likely outweigh any  incremental  benefit on hemoglobin recovery. Further, IV iron will be given as a 
single total dose infusion, which provides complete restoration of usable iron for >4 weeks.45,46 For anemias requiring 
erythropoietic  stimulation, EPO will be given as a single 40,000 unit dose after ensuring restoration of iron stores, a 
strategy that has resulted in sustained hemoglobin improvement and is widely used in anemia clinics.46,47 Patients with 
laboratory evidence (i.e. ferritin > 1000 ng/mL) or clinical conditions (i.e. hemochromatosis) indicating states of iron 
overload will not receive iron supplementation prior to EPO therapy.  A single EPO dose carries a lower risk for 
thrombotic complications than repeat dosing, which is particularly relevant in the critically ill.  
Regarding  the safety of IV iron (i.e. low molecular weight iron dextran), this medication is used extensively in modern 
medical practice.  The estimated incidence of serious adverse events (SAEs)  is less than [ADDRESS_519127] dose of 25 mg will be given over 5 
minutes to ensure no symptoms of adverse r eaction with continuous assessment by [CONTACT_10327], including 
continuous monitoring of pulse oximetry, heart rate, and blood pressure (continuously for those with an invasive arterial 
catheter, and every 5 minutes for those without) and visual inspect ion of the patient for rashes or signs of physical 
and/or respi[INVESTIGATOR_1506]. At the discretion of the clinical team, patients deemed to be at high -risk for infusion 
reactions (e.g. inflammatory arthritis) may be given steroid premedication (e.g. 125 mg methylprednisolone).  If a patient 
develops or is suspected of developi[INVESTIGATOR_411599], therapy will be immediately halted. All infusion reactions 
will be immediately reported to study personnel for accurate characterization and reporting . Those deemed to have a 
minor infusion reaction (i.e. rash in absence of hemodynamic or respi[INVESTIGATOR_7798]) will be observed for 15 
minutes for signs of clinical progression.  If symptoms abate within 15 minutes, the infusion will be restarted at a lowe r 
rate.  If the patient has persistent mild symptoms, recurrent symptoms, and/or urticaria, they will be treated with an H2 -
blocker antihistamine (e.g. ranitidine 50 mg), in accordance with institutional policy, prior to restarting the infusion at a  
lower rate. If there is concern for a moderate infusion reaction or further symptom progression (e.g. hypotension, 
worsening rash), patients may also receive IV steroids (e.g. methylprednisolone 1 -2 mg/kg) +/ - a 1L bolus of intravenous 
isotonic crystalloid (at d iscretion of ICU team) in addition to H2 blockers. Symptoms should abate completely prior to re -
challenging with IV iron, and an alternative iron formulation with comparable dosing should be considered (e.g. iron 
sucrose).  Should a severe reaction be obse rved (i.e. respi[INVESTIGATOR_1506], anaphylaxis), the patient will receive immediate 
treatment with IV epi[INVESTIGATOR_238] (e.g. 0.1 mg) and additional cardiopulmonary support as dictated by [CONTACT_411639].  Patients without any apparent reaction to IV iron w ill be observed clinically for [ADDRESS_519128] every 15 minutes, continuous pulse 
oximetry, and telemetry. Those experiencing infusion reactions will be observed for lo nger times as dictated by [CONTACT_411640].  It is commonly thought that iron may predispose patients to bacterial infections;44 however, 
this has not been shown in multiple clinical trials in the critically ill.32,48,49 Out of an abundance of caution, we will exclude 
patients with uncontrolled sepsis, defined as <48 hours of appropriate antimicrobial therapy and/or lack of definitive 
source control.  
Regarding EPO, several actions are being taken to mitigate risk: 1) excluding patients with relative contraindications to 
EPO therapy (e.g. pregnancy, active thrombosis, an inability to receive VTE pharmacoprophylaxis, active myocardial 
ischemia, poorly co ntrolled hypertension, recent stroke); 2) tailoring pharmacotherapy to anemia etiology, such that 
EPO is not administered to patients that are likely to mount an appropriate erythropoietic response with iron therapy 
alone; and 3) providing only a single do se of EPO therapy for those receiving this therapy. Of note, the optimal dosing of 
EPO is unknown in the critically ill, though clinical trials in surgical patients have shown that a single dose of EPO result s 
in sustained hemoglobin improvement.47  All adverse events will be closely evaluated by [CONTACT_411641].  Similar to iron, EPO will be administered by [CONTACT_411642]. Iron will be co -administered immediately prior to EPO to ensure 
adequate iron stores for EPO -induced augmentation of bone m arrow erythropoiesis.   Patients will be continuously 
monitored at the time of administration for immediate adverse effects (e. g. cutaneous reactions, hypertension, 
dizziness, nausea).  Those without immediate reaction will be observed clinically for [ADDRESS_519129]. Matthew Warner   CONFIDENTIAL  
 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR ENDPOINT S 
frame: [ADDRESS_519130] -
hospi[INVESTIGATOR_059]]  
To assess the impact of the intervention 
on cognitive function after critical illness  MoCA -BLIND [Time frame: [ADDRESS_519131] -hospi[INVESTIGATOR_059]]  Recommended as part of Core 
Outcome Measurement Set (COMS) 
for ICU survivors  
To assess the impact of the intervention 
on mental health after critical illness  HADS, IES -R [Time frame: [ADDRESS_519132] -hospi[INVESTIGATOR_059]]  Recommended as part of Core 
Outcome Measurement Set (COMS) 
for ICU survivors  
To assess the impact of the intervention 
on RBC transfusions  Allogeneic RBC transfusions (units) 
[Time frame: hospi[INVESTIGATOR_059], through 
3-months post -hospi[INVESTIGATOR_059]]  Anemia management may directly 
result in reductions in RBC 
transfusions  
To assess the impact of the intervention 
on unplanned hospi[INVESTIGATOR_411600] [ADDRESS_519133] -hospi[INVESTIGATOR_059] . Unplanned hospi[INVESTIGATOR_5394] 
[Time frame: 12 months]  Previous data suggests that anemia 
treatment with iron therapi[INVESTIGATOR_411601] [ADDRESS_519134] -
hospi[INVESTIGATOR_411602]-cause mortality [Time frame: 12 
months]  Previous data suggests that IRON 
and EPO may reduce mortality 
during and after critical illness  
 
 
 
[ADDRESS_519135] care.  
Patients satisfying inclusion/exclusion criteria,  or their legal proxies , will be approached by [CONTACT_411643]. Participants will be randomized 1:[ADDRESS_519136] care using a 
stratified permuted block design by [CONTACT_411644] (iron -responsive or not)  and ICU admission indication  (surgical vs. 
non-surgical).  The intervention arm is multi -faceted with 3 primary components: 1) Optimized phlebotomy , defined by 
[CONTACT_411645] (i.e. 0.[ADDRESS_519137] 3 -10 ml per laboratory order) and closed -loop blood sampling 
(eliminates 10 ml waste volume per draw), all performed by a dedicated phlebotomy team independent from the 
treatment team; 2) Decision support aids , including visual and electronic alerts reminding the care team to minimize 
non-essential laboratory testing and mitigate patient -specific bleeding risk (e.g. stress ulcer prophylaxis in high -risk 
patients); and 3) Pharmacologic  anemia treatment (given immediately  following enrollment when hemoglobin first 
observed <10 g/dL) targeted to [ADDRESS_519138] groups: 1) anemias responsive to iron supplementation  alone (i.e. acute blood 
loss, true iron deficiency [i.e. ferritin <100 ng/ml, transferrin saturation < 20%]),  and 2) anemias requiring erythropoietic 
stimulation  (e.g. anemia of inflammation, anemia of renal disease). Etiology of anemia will be determined immediately 
prior to randomization  upon review of laboratory values (i.e. iron studies) and clinical history (i.e. admi ssion diagnoses, 
surgery/acute blood loss) with treatment decisions adjudicated pre -randomization by [CONTACT_978] [INVESTIGATOR_12749] -I’s. Subjects then 
randomized to the intervention arm will receive pharmacologic anemia treatment in accordance with their anemia 
etiology.  Patients with anemias responsive to iron supplementation  will receive a single total dose infusion (1000 mg) of 
intravenous (IV) iron dextran. Patients with anemias requiring erythropoietic stimulation  will receive a single dose of 
40,000 units of subcutane ous EPO , which will be immediately preceded by 1000 mg of IV iron dextran to replenish 
usable iron stores if the ferritin level is < 1000 ng/ml .  All patients randomized to the intervention group will receive 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519139]. Matthew Warner   CONFIDENTIAL  
 either IV iron, EPO, or both.  Targeted pharmacologic anemia therap ies are being employed  given that anemia in acute 
blood loss/post -surgery and true iron deficiency is iron -restricted and responds to iron supplementation alone; hence, 
the potential harms of EPO (e.g. thrombosis) likely outweigh benefits.   
 
Outcome assessment :  
In-person outcome assessments will occur at [ADDRESS_519140] -hospi[INVESTIGATOR_059], with investigators and 
outcome assessors blinded to treatment allocation. The primary outcome  will be the mean difference in hemoglobin  
between groups at 1 month. Differences in hemoglobin concentrations will also be assessed at ICU discharge, hospi[INVESTIGATOR_7954], and 3 month follow -up. Secondary outcomes  will include changes in phlebotomy practice  (i.e. number of 
draws, total volume of draws) during hospi[INVESTIGATOR_411603] 1 and 3 months, employing the NHLBI -
funded Core Outcome Measurement Set (COMS) for survivors of critical illness (aim 2b).23,50 This includes validated 
measures of physical function (6MWD, ADL survey), cognition (Montreal Cognitive Assessment Blind), mental health 
(Hospi[INVESTIGATOR_5620], Impact of Events Scale -Revised), and quality of life (EQ -5D).  Additionally , as an 
optional study component, we will solicit patients to wear  an activity monitor ( Actigraph ) on their wrist for 4 consecutive 
days at 1 and 3 -month s, from which we will capture daily step counts and energy expenditure measurements.  We will 
also assess several Epic -embedded patient -reported outcomes (i.e. PROMIS) with multidimensional computerized 
adaptive testing (i.e. PROMIS CAT), laying the groundwork for validation in critical illness research.   Differences in RBC 
transfusion rates  will be assessed through [ADDRESS_519141] -hospi[INVESTIGATOR_059].  Research samples obtained will be store d for potential biomarker assessment 
(i.e. hepcidin, IL -6, C-reactive protein) for future mechanistic studies  on anem ia development and recovery in critical 
illness survivors .  
 
Sample size estimation :  
Power/sample size are calculated to detect a difference in the primary endpoint of hemoglobin at 1 month  follow -up. 
Preliminary data show mean (standard deviation) hemoglobin levels of 10. 8 (1.5) g/dL at 1 month among 636 patients 
with similar inclusion/exclusion criteria receiving standard care. A total sample size of 74 (37 per group) provides 80% 
power to detect 1.0 g/dL improvement using a two-sample unequal variances t -test with 2 -sided alpha of 0.05  to 
compare 1 month hemoglobin between randomized arms.  Actual power is expected to be higher under the analysis 
approach, adjusting for pre -randomization prognostic variables to reduce residual variation. If adjustment variables 
account for 25% of the variation in 1 month hemoglobin (R2 for relationship between pre -randomization adjustment 
variables and outcome = 0.25), the sample size of 37 per group provides 90% power to detect a 1.0 g/dL improvement 
using analysis of covariance with 2 -sided alpha of 0.05. While the analysis uses a linear mixed -effects model (LMM), 
power is not appreciably different for the LMM as compared to the unequal variances t -test or ANCOVA described here . 
Given expected dropout of up to 25% (death, loss to follow -up) resulting in loss of information , 100 subjects will be 
enrolled.  
 
Statistical considerations :  
The primary outcome is hemoglobin measured repeatedly on subjects at ICU discharge, hospi[INVESTIGATOR_2345], and [ADDRESS_519142] on 1 month  hemoglobin is the primary outcome; other time -points will reflect secondary outcomes. As 
the functional form of hemoglobin over time is un known, a discrete time representation will be used. The model will 
adjust for pre -randomization hemoglobin, age, sex, anemia etiology, and medical vs surgical ICU setting to reduce 
residual variation and improve precision of the estimated treatment effect.   
Dropout or non -response including skipped study visit and death represent two forms of missing data.  Dropout or non -
response unrelated to death at ICU discharge and hospi[INVESTIGATOR_411604] -BR                             Version 5.[ADDRESS_519143]. Matthew Warner   CONFIDENTIAL  
 withdrawal of consent.  We assume dropout (unrelated to death) while in the ICU is missing completely at random 
(MCAR); patients withdrawing consent prior to observation of hemoglobin outcome at ICU discharge will be excluded 
from the analysis.  Those drop pi[INVESTIGATOR_411605] (MAR) with missingness 
possibly related to adjustment covariates , arm, or prior observed hemoglobin values.  Analyses using LMM assume 
dropout, nonresponse, or skipped visits are MAR.  
We anticipate up to 10% ICU mortality (despi[INVESTIGATOR_411606]) ; such subjects 
will not have observed hemoglobin outcomes. We also anticipate additional post -ICU discharge mortality. In the primary 
analysis, we assume missing data due to death is MAR.  Those with ICU mortality will have ICU discharge hemoglobin 
multiply imputed under the MAR assumption.  Thereafter, LMMs assum e additional missing data at other times are 
MAR.  In secondary approaches to the analysis  of hemoglobin, we use a worst -case imputation approach, to impute 
hemoglobins as the worst possible outcome following death.  After imputation, if residuals are not reasonably normally 
distributed, a generalized linear mixed effects proportional odds mode l will be used or individual timepoints may be 
assessed by [CONTACT_80094] -sum test without covariate adjustment.  A similar approach using proportional odds models 
or Wilcoxon rank -sum test will apply to functional outcomes which are not expected to satisfy  regression assumptions 
including normality of residuals.  Similar approaches assuming MAR and MNAR will be applied to missing functional 
outcome data.  
4.[ADDRESS_519144] control (standard 
care).  The control group will receive standard care without an active placebo for several reasons: 1) the multifaceted 
nature of the study intervention makes it difficult to design a placebo for each unique intervention element, particularly 
clinical decision sup port and optimized phlebotomy); 2) the expenses associated with administering a placebo for 
pharmacologic agents (i.e. iron, E PO) are considerable and would not be possible through the  NIH K -23 funding 
mechanism; and 3) this is a pi[INVESTIGATOR_411607] a larger, multi -center definitive clinical trial in which we would 
have the resources available for placebo administration of pharmacologic therapi[INVESTIGATOR_014].  Superiority will be assessed as the 
goal is to improve anemia in the critically ill, given that the problem of anemia is extremely prevalent in the  ICU, rather 
than to prove non -inferiority against standard care.   
 
4.3 JUSTIFICATION FOR DO SE 
 
IV iron given as a single total dose infusion of 1000 mg of IV low molecular weight iron dextran, which provides complete 
restoration of usable iron for >[ADDRESS_519145] 
visit shown in the S chedule of Activities (SoA), Section 1.[ADDRESS_519146] meet all the following criteria:  
1. Provision of signed and dated informed consent form  (may be completed by [CONTACT_411646] , i.e. sedation/intubation)  
2. Stated willingness to comply with all study procedures and availab ility for the duration of the study , including 
follow -up assessments  
3. Male or female, age  > 18 years  
4. Current ICU admission at Mayo Clinic [COMPANY_002]ster   
5. Current ICU duration < [ADDRESS_519147] -hospi[INVESTIGATOR_411608]  
7. Moderate -to-severe anemia (i.e. hemoglobin concentration < 10 g/dL) at the time of enrollment, with the 
hemoglobin concentration assessed no more than 24  hours prior to  enrollment .  If RBC transfusion has been 
administered between the qualifying hemoglobin assessment and enrollment, a repeat hemoglobin will be 
required prior to enrollment to ensure that it remains < 10 g/dL.   
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. IV iron or any ESA use (i.e.  darbepoetin , Aranesp, erythropoietin , Epogen, Procrit , Retacrit ) within 30 days of 
enrollment . Oral iron is permitted (e.g. oral iron supplements, multivitamin with iron)  
2. Severe anemia prior to hospi[INVESTIGATOR_059] (i.e.  hemoglobin consistently <9 g/dL in the 90 days prior to  admission) . If 
hemoglobin is not available or if hemoglobin is ≥ 9 g/dL at any time within 90 days prior to enrollment, then this 
criterion is not met, and the patient may be enrolled   
3. Known allergic reactions to IV iron or any EPO agent  
4. Inability to complete outcome assessments (i.e. not expected to survive hospi[INVESTIGATOR_059], unable to make follow -
up appointments, non-ambulatory  status preceding hospi[INVESTIGATOR_059] , dementia or other severe  cognitive 
impairment, visual impairment i.e. blind or legally blind, non-English speaking)  
5. Pregnancy  or breastfeeding at time of enrollment  given unclear safety of EPO   
6. Inability to receive pharmacologic venous thromboembolic prophylaxis  except in patients with acute blood loss 
anemia (i.e. recent surg ery or gastrointestinal bleeding , extracranial bleeding)  
7. Active  or suspected  thrombosis (i.e. DVT, pulmonary embolism, acute arterial thrombus ) within 3 months  except 
in patients with acute blood loss anemia (i.e. recent surgery, gastrointestinal bleeding, extracranial bleeding)  
8. Uncontrolled sepsis (i.e. lack of definitive source control  and/or <48 hours of appropriate antimicrobial therapy ) 
9. Having received ≥10 units of allogeneic RBCs in the 48 hours before enrollment  
10. Acute coronary syndrome  (STEMI or NSTEMI)  or ischemic stroke within 3 months  except in patients with acute 
blood loss anemia (i.e. recent surgery, gastrointestinal bleeding, extracranial bleeding)  
11. Weight less than [ADDRESS_519148]. Matthew Warner   CONFIDENTIAL  
 required to ensure transparent reporting of screen failure participants , to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details, and eligibility criteria . 
 
Individuals  who do not meet the criteria for participation in this trial (screen failure) because of subsequent hemoglobin 
assessments which prove exclusionary (i.e. hemoglobin > 10 g/dL)  may be rescreened  as long as they remain in the ICU 
with a duration not to exceed 7 days at the time of enrollment . Rescreened participants should be assigned the same 
participant number as for the initial screening.   
 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTIO N 
Recruitment : Trained study coordinators from the Anesthesia Clinical Research Unit will receive daily electronic alerts 
notifying them of Mayo Clinic [COMPANY_002]ster ICU patients > [ADDRESS_519149] recent hemoglobin value <10 g/dL 
(infrastructure for these near real -time electronic alerts [2 -5 minute delay] are already in place through the ICU 
DataMart).  Patients may be present in any adult ICU .  These patients will then be screened through Electronic Health 
Record ( EHR) review by [CONTACT_411647]/exclusion criteria. Patients 
meeting inclusion/exclusion criteria will be approached by [CONTACT_411648] , or by [CONTACT_411649]/or IRB policies in the setting of COVID -19-related clinical practice/research 
modifications.  Study coordinators will meet with p atient  or their legal proxies in the case of a patient’s inability to 
directly communicate with study personnel (i.e. deep sedation) . The study coordinator will review the research study in 
detail, explaining the purpose of the study including iron and erythropoietin administration, additional necessary 
phlebotomy and needed follow up  post hospi[INVESTIGATOR_411609] .  It will be made clear that all participants will receive routine 
clinical care regardless of whether they 1) agree to participate in the trial, or 2) are randomized to the active treatment 
arm. The informed consent discussion will occur between the patient  and a member of the study team at the patient’s 
bedside during ICU admission as soon as the patient meets eligibility criteria (i.e. within 24 hours). The patient/proxy will 
be allowed time to have all their questio ns answered  questions answered and assure no exclusions to enrollment are 
identified.   Written informed consent will be obtained by [CONTACT_411650]. Signed 
consent forms will be scanned into the patient’s HER and a copy will be provided to the study participant . No 
information will be used from patients that have not given consent to use their medical information.   In the event the 
LAR consents on behalf of the subject, the study coordinator will make sure and visit with the subject once functional 
status  is reestablished to assure the subject wants to continue with participation. By [CONTACT_159753], the subject  may/may not 
have already received study drug, so all they would be affirming is their willingness to continue with the follow up 
visits/labs/ questionnaires.  
Retention:  A high -level of patient follow -up (>75%) is necessary for success, including in -person evaluations for 
hemoglobin laboratory draws. To achieve this, we have limited the study to residents  residing locally (i.e. patients that 
receive routine medical cares in Mayo Clinic [COMPANY_002]ster or the regional Mayo Clinic Health System) , a unique population 
with a high -level of community engagement in clinical research and a high -level of post -hospi[INVESTIGATOR_411610] a nd its affiliated regional sites. Similar studies of Olmsted County residents, 
including those with laboratory draws, have achieved >90% retention.51 Additionally, we are partnering with the Mayo 
Clinic ICU Rehabilitation Program (MCIRP) .  The MCIRP is a post -ICU clinic staffed by a physician, advanced ICU care 
nurse practitioner, ICU pharmacist, and occupational therapi[INVESTIGATOR_541], with the recent addition of a nurse coordinator. In the 
current care model, survivors of critical illness, identified through real -time electronic data “sniffers”, and their family 
members are appro ached by [CONTACT_411651][INVESTIGATOR_2345]. Patients are evaluated  
within 6 months of hospi[INVESTIGATOR_256947] a less than 5% no -show rate for enrolled participants and greater than 90% 
retention for additional visits. Multi -dom ain functional outcomes (physical, cognitive, mental health, quality of life) are 
assessed at each study visit in accordance with the NHLBI -funded improveLTO Core Outcome Measure Set 
(http://improvelto.com ). Of note, with COVID -[ADDRESS_519150] resulted in >90% cohort retention through [ADDRESS_519151] including proxies, 
frequent patient engagement, reminder notifications  (e.g. reminder phone calls starting 2 weeks before each follow -up 
appointment and subsequently a phone call 1 week and 1 day before the  appointment) , remuneration (i.e. $25 per 
follow -up visit  – [ADDRESS_519152] -hospi[INVESTIGATOR_059] ), and vouchers for parking  (4-hour parking passes, given at 
each follow -up visit) . Recognizing that some patients may die or be lost to contact [CONTACT_411652] (~25%), 
we have increased our study sample size from 74 to 100 participants.    
  
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
The intervention arm is multi -faceted with 3 primary components:  
1) Optimized phlebotomy , defined by [CONTACT_411645] (i.e.  0.1-[ADDRESS_519153] 3 -10 ml per laboratory 
order) and closed -loop blood sampling , all performed by a dedicated phlebotomy team independent from the 
treatment team . This intervention simply requires communication with the phlebotomy team rather than any 
direct change to patient care.   
2) Decision support .  This includes:  
a. A visual clinical support tool (appendix) urging the clinical team to minimize laboratory assessments and 
optimize patient bleeding risk.  This will be available by [CONTACT_411653]’s bedside.   
b. A daily rounding checklist (appendix) accompanied by [CONTACT_411654] (2-minutes) between trained 
study coordinators and the ICU care team during clinical rounds to reiterate the purpose of the study .  
The checklist will be available at the clinical workstations for the ICU team.  
c. Epic direct messages sent twice per day (targeting day and night providers) with the information from 
the visual support tool to retitrate the purpose of the study . 
3) Pharmacologic  anemia treatment .  These therapi[INVESTIGATOR_411611] [ADDRESS_519154] groups:  
a. Anemias responsive to iron supplementation  alone .  This includes patients with anemia secondary to 
acute blood loss  > 500 ml and patients with iron deficiency anemia ( i.e. ferritin <100 ng/ ml or transferrin 
saturation < 20% ).   
• Patients with iron -responsive anemias will receive a single total dose infusion (1000 mg) of 
intravenous (IV)  low molecular weight  iron dextran  (INFeD)   
• This medication is diluted in 500 ml of 0.9% saline. A [ADDRESS_519155] dose (12.5) ml is administered 
over 5 minutes to ensure no immediate hypersensitivity reaction, followed by [CONTACT_411655] 1 -2 hours (not to exceed 1000 mg/hr). This med ication will be given in 
accordance with Mayo Clinic administration guidelines.  
b. Anemias requiring erythropoietic stimulation . This includes anemia not secondary to acute blood loss or 
iron deficiency  (e.g. anemia of inflammation, anemia of renal disease). Etiology will be determined 
immediately prior to randomization  upon review of laboratory values (i.e. iron studies) and clinical 
history (i.e. admission diagnoses, surgery/acute blood loss) with treatment decisions adjudicated pre -
randomization by [CONTACT_978]  [INVESTIGATOR_411612] C o-I’s should the PI [INVESTIGATOR_49471].   
• Patients w ithout iron -responsive anemias  will receive a single dose of 40,000 units of 
subcutaneous EPO  (Retacrit) .  For those with ferritin less than 1000 ng/ml they will also receive 
[ADDRESS_519156]. Matthew Warner   CONFIDENTIAL  
 invariably be mobilized secondary to EPO stimulation.  EPO will be given in accordance with 
Mayo Clinic administration guidelines .   
 
 
6.1.2  DOSING AND ADMINISTRATION  
 
Iron dextran shall be administered intravenously as a single dose of 1000 mg ([ADDRESS_519157] dose followed by 975 mg 
completion dose). EPO shall be administered as a single dose of 40,000 units subcutaneously. There is no patient -specific 
dose selection. Doses  do not need to be modified in relation to meals.  
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.[ADDRESS_519158] the research pharmacy 
regarding the need for IV iron +/ - EPO.  This will be distributed form the research pharmacy  to the patient’s bedside 
followed by [CONTACT_411656]. Study coordinators will be available to ensure appropriate 
administration.  Any unused and untampered agents will be immediately returned to the pharmacy.  
 
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
Low molecular weight iron dextran (INFe D®, [COMPANY_013], Inc. ), details from package insert:  INFeD (iron dextran injection 
USP) is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or 
intramuscular use. Each mL contains the equivalent of 50 mg of elemental iron (as an iron dextran complex), 
appro ximately 0.9% sodium chloride, in water for injection. Sodium hydroxide and/or hydrochloric acid may have been 
used to adjust pH. The pH of the solution is between 5.2 and 6.5.  
 
EPO (Retacrit ®, Hospi[INVESTIGATOR_20116], Inc ), details from package insert: Epoetin alfa -epbx is a 165 -amino acid erythropoiesis -
stimulating glycoprotein manufactured by [CONTACT_12060]. It has a molecular weight of approximately 
30,400 daltons and is produced in Chinese Hamster Ovary (CHO) cell line. The product contai ns the identical amino acid 
sequence of isolated natural erythropoietin. RETACRIT (epoetin alfa -epbx) injection for intravenous or subcutaneous 
administration is a sterile, clear, colorless soluti on in single -dose vials, formulated with an isotonic sodium 
chloride/sodium phosphate  buffered solution. Each 1 mL single -dose vial of 2,000, 3,000, 4,000, and 10,000 Units of 
epoetin alfa -epbx contains calcium chloride dihydrate (0.01 mg), glycine (7.5 mg), isoleucine (1 mg), leucine (1 mg), L -
glutamic acid (0.25 mg), phenylalanine (0.5 mg ), polysorbate 20 (0.1 mg), sodium chloride (2.4 mg), sodium phosphate 
dibasic anhydrous (4.9 mg), sodium phosphate monobasic monohydrate (1.3 mg), and threonine (0.25 mg ), in Water for 
Injection, USP. Each 1 mL vial of 40,000 Units of epoetin alfa -epbx contains calcium chloride dihydrate (0.01 mg), glycine 
(7.5 mg), isoleucine (1 mg), leucine (1 mg), L -glutamic acid (0.25 mg), phenylalanine (0.5 mg), polysorbate 20 (0.1 m g), 
sodium chloride (2.2 mg), sodium phosphate dibasic anhydrous (5.7 mg), Reference ID: 4263015 sodium phosphate 
monobasic monohydrate (1.5 mg), and threonine (0.25 mg), in Water  
 
6.2.[ADDRESS_519159] STORAGE AND STABILITY  
 
Iron (INFeD®): Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).  
 
EPO (Retacrit®): Store at 36°F to 46°F (2°C to 8°C). Do not freeze. Do not shake. Do not use RETACRIT that has been 
shaken or frozen. Store RETACRIT vials in the original carton until use to protect from light . 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519160]. Matthew Warner   CONFIDENTIAL  
  
 
6.2.4  PREPARATION  
 
No preparation (thawing, diluting, mixing, reconstitution) is required.  
 
6.3 MEASURES TO MINIMIZE BIAS : RANDOMIZATION  AND BLINDING  
 
Participants will be randomized 1:[ADDRESS_519161] of care using a stratified permuted block design 
by [CONTACT_411644] (iron responsive vs. not) and ICU admission indication (surgical vs. non -surgical). Randomization will 
occur electronically  using the REDCap randomization module.  Randomization lists will be developed by [CONTACT_411657].  Study staff involved in patient care are unable to access randomization 
lists in advance and therefore are un likely to predict future randomization/assignment . Clinicians and subjects  will not 
be blinded to study interventions. However, all data analysts will be blinded to treatment allocation  while the study is 
ongoing .  
 
6.[ADDRESS_519162]’s  receipt of pharmacologic therapy (iron +/ - EPO).  This will be assessed on 
study day 1 by [CONTACT_2710]. The proportion of subjects successfully receiving the intervention will be reported 
(number, %).  Similarly, the proportion of subjects seen for 1 -month and 3 -month follow -up assessments will be 
reported.  
 
6.5 CONCOMITANT THERAPY  
 
For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly 
authorized/licensed clinician. Medications to be reported at baseline are all concomitant prescription medications, over -
the-counter medications and supplements .  Medications to be reported at daily visits are only to include if the subject 
has received iron or EPO/darbepoetin on these days.  
 
Subjects who received iron therapi[INVESTIGATOR_014] (exclusive or multivitamins with iron) or erythropoiesis stimulating agents (i.e.  
darbepoetin  , erythropoietin) within [ADDRESS_519163] already been receiving anemia 
treatment prior to enrollment.    
 
 
6.5.1  RESCUE MEDICINE  
 
Not applicable  
 
7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  DISCONTINUATION /WITHDRAWAL .  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
 
Discontinuation from the pharmacologic therapi[INVESTIGATOR_014] (i.e. iron, EPO) does not mean discontinuation from the study, and 
remaining study procedures should be completed as indicated by [CONTACT_4690].   If a clinically sig nificant finding is 
identified (including, but not limited to severe allergic reactions during medication administration ) after enrollment, the 
investigator or quali fied designee will determine if any change in participant management is needed. Any new clinically 
relevant finding will be reported as an adverse event (AE) . 
 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519164]. Matthew Warner   CONFIDENTIAL  
 The data to be collected at the time of study intervention discontinuation will include the following:  
- Reason for discontinuation  
- Date and time of discontinuation  
- Subject -initiated or investigator -initiated discontinuation  
- Changes in vital signs or clinical status that prompted discontinuation  
- Adverse events  
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Participant s are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue  or withdraw a participa nt from  the study for the following reasons : 
 
• Significant study intervention non-compliance  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such 
that continued participation in the study would not be in the best interest of the participant  
• If the participant  meets an exclusion criterion (either newly developed or not previously recognized) that 
precludes further study participation  
The reason for participant discontinuation  or withdrawal from the study will be recorded on the appropriate  Case 
Report Form ( CRF). Subjects who sign the informed consent form and are randomized but do not receive the study 
intervention may be replaced.  Subjects who sign the informed consent form, and are randomized and receive the study 
intervention , and subsequently withdraw, or are withdrawn or discontinued  from the study, will not be replaced.  
7.[ADDRESS_519165] be taken if a participant fails to return to the clinic for a required study visit:  
• The site will attempt to contact [CONTACT_62541] 1 week  and counsel the 
participant on the importance of maintaining the assigned visit schedule and ascertain if the participant wishes 
to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every effort to regain 
contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the 
participant’s last known mailing address or local equivalent methods). These contact [CONTACT_411658]’s medical record or study file.  
• Should the participant  continue to be unreachable, they  will be considered to have withdrawn from the study 
with a primary rea son o f lost to follow -up. 
 
 
8 STUDY ASSESSMENTS AND PROCEDURES  
 
8.1 EFFICACY ASSESSMENTS  
 
Study subjects will undergo the  following procedures/evaluations:  
• Baseline assessments . Medical history, surgical history, demographic features, height, weight, concomitant 
medication review and cu mulative fluid balance, including previous exposure to blood transfusions , ADL survey .   
 
Protocol PABST -BR                             Version 5.[ADDRESS_519166]. Matthew Warner   CONFIDENTIAL  
 • Biological specimen collection and laboratory evaluations . Following enrollment, study labs will be obtained 
according to table 1.3.  CBC and creatinine is often done daily as standard of care. If the subject has a CBC and 
creatinine value obtained within the prior 24 hrs, this result  may be used . However, if they  received a unit of 
blood after that timepoint , the CBC would need to be repeated.   All subjects will return for followup 
assessments and blood draws as noted in table 1.3.  The research  blood samples  for storage and future research  
will be obtained ([ADDRESS_519167] ) at enrollment and post -hospi[INVESTIGATOR_411613].  These samples will be cold -stored.  
• Administration of questionnaires or other instruments .  Subjects will undergo functional outcome assessments 
in accordance with the NHLBI -supported COMS of critical illness.  These measures, either comprehensively or in 
part (as outlined in 1.3), will be obtained at enrollment, hospi[INVESTIGATOR_2345], and [ADDRESS_519168] s will undergo the following procedures/evaluations:  
• Vital signs . Temperature, pulse, respi[INVESTIGATOR_1520], blood pressure , continuo us telemetry, oxygen saturations will be 
monitored during administration of iron and EPO for those in the intervention group as outlined in section 2.3.  
All subject s will receive standard ICU monitoring throughout their stay in the ICU.   
  
• Weight . Subject s < 40 kg will be excluded due to unclear safety of 40,000 unit of EPO in persons with low 
weights  
 
• Assessment of adverse events . Medical records will be reviewed daily for evaluation of adverse events.  Adverse 
events will be indicated on the data forms for the study and on the specific adverse event report forms and all 
serious adverse events will be reported to the IRB within 24 hours of the research team learning about the event 
followed by a more deta iled written report to the IRB.   The following information about adverse events will be 
collected:   1) the onset and resolution of the event, 2) an asse ssment of the severity or intensity of the event, 3) 
an assessment of the relationship of the event to the intervention, and 4) any action taken because of 
event.  The PI [INVESTIGATOR_411614] 7 days of discovery.  
 
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERSE EVENTS  (AE)  
 
Adverse event means any untoward medical occurrence associated with the use of an intervention in humans, whether 
or not considered intervention -related (21 CFR 312.32 (a)).  
As our subject population is by [CONTACT_108] ‘critically ill’, it is expected that they will have many unrelated adverse health 
events during their hospi[INVESTIGATOR_4408]. Therefore, we will limit the scope of our adverse event monitoring and recording to 
focus on the following  conditions :  
➢ Study drug infusion reactions  
➢ Venous thromboembolic disease   
➢ Myocardial infarction  
➢ Non -hemorrhagic stroke  
➢ Bloodstream infections   
➢ Hypertensive urgency or emergency in the 1 hour after study drug administration (i.e. SBP > 200 or SBP 
increase by > 40 mmHg from the time of infusion start)  
 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519169]. Matthew Warner   CONFIDENTIAL  
  
8.3.2  DEFINITION OF SERIOUS ADVERSE EVENTS  (SAE)  
 
An adverse event ( AE) or suspected adverse reaction is considered "serious" if, in the view of either the investigator or 
sponsor, it results in any of the following outcomes: death, a life -threatening adverse event, inpatient hospi[INVESTIGATOR_8448], or a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions.  
Serious adverse events (SAEs) will be defined as:  
➢ Death, believed to be related to the study procedures, or a death that is unexpected considering the 
acuity of a  subject . 
➢ A life -threatening experience, including severe infusion reactions, believed to be related to the study 
procedures.  
➢ Persistent or significant disability or incapacity that is of greater frequency or severity than what would 
be normally expected in the course of critical illness.  
➢ An event that jeopardizes the human subject and may require medical or surgical treatment to prevent 
one of the preceding outcomes and is not expected in the subject’s ICU course.  
 
8.3.3  CLASSIFICATION OF AN ADVERSE E VENT  
 
[IP_ADDRESS]  SEVERITY OF EVENT  
 
For adverse events ( AEs), the following guidelines will be used to describe severi ty.  
 
• Mild  – Events require minimal or no treatment and do not interfere with the participant ’s clinical course.   
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic measures. Moderate 
events may cause some interference with the subject’s clinical course . 
• Severe  – Events interrupt a participant ’s clinical course  and may require systemic drug therapy or other 
treatment. Severe events are usually potentially life -threatening or incapacitating.  
 
[IP_ADDRESS]  RELATIONSHIP TO STUDY INTERVENTION  
 
All adverse events ( AEs) must have their relationship to study intervention  assessed  by [CONTACT_411659]/her clinical judgment.  The degree of certainty about 
causality will be graded using the categories below. In a clinical trial, the study product must always be suspect.  
 
• Definitely Related  – There is clear evidence to suggest a causal relationship, and other possible contributing 
factors can be ruled out. The clinical event  occurs in a plausible time relationship to study intervention  
administration and cannot be explained by [CONTACT_9153]. The response to 
withdrawal of the study intervention  (dechallenge) should be clinically plausible. The event must be 
pharmacologically or phenomenologically definitive, with use of a satisfactory rechallenge procedure if 
necessary.  
• Probably Related  – There is evidence to suggest a causal relationship, and the influence of other factors is 
unlikely. The clinical event  occurs within a reasonable time after  administration of the study intervention , is 
unlikely to be attributed to concurrent disease or other drugs or chemicals, and follows a clinically reasonable 
response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.  
 
Protocol PABST -BR                             Version 5.[ADDRESS_519170]. Matthew Warner   CONFIDENTIAL  
 • Potentially  Related  – There is some evidence to suggest a causal relationship (e.g., the event occurred within a 
reasonable time after administration of the trial medication). However, other factors may have contributed to 
the event (e.g., the participant ’s clinical condition, other concomitant events). Although an AE may rate only as 
“possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to 
“probably related” or “definitely related”, as appropriate.  
• Unlikely to be related  – A clinical event  whose temporal relationship to study intervention  administration makes 
a causal relationship improbable (e.g., the event did not occur within a reasonable time after administration of 
the study intervention ) and in which other drugs or chemicals or underlying disease provides plausible 
explanations (e.g., the participant ’s clinical condition, other concomitant treatments).  
• Not Related  – The AE is completely independent of study  intervention  administration, and/or evidence exists 
that the event is definitely related to another etiology. There must be an alternative, definitive etiology 
documented by [CONTACT_15370].  
 
[IP_ADDRESS]  EXPECTEDNESS  
 
The PI [INVESTIGATOR_21190] ( AE) is expected or unexpected.  An AE will be 
considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information 
previously described for the study intervention . 
8.3.4  TIME PERIOD AND FR EQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the attention of study personnel 
during study visits and interviews of a study participant  presenting for medical care, or upon review by a study monitor.  
 
As noted earlier, for this study we plan to observe for a specific set of AEs and this information will be captured on the 
appropriate  case report form  (CRF). Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to study product (assessed only by [CONTACT_8703] a 
diagnosis), and time of resolution/stabilization of the event. All AEs will be followed to adequate resolution.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of 
severity  to be performed.  
 
Study coordinators  will record all  listed reportable events with start dates occurring any time after informed consent is 
obtained through 3 -months after hospi[INVESTIGATOR_059] .  At each study visit, the investigator will inquire about the occurrence 
of AE/SAEs since the last visit.  Events will be followed for outcome information until resolution or stabilization.  
 
 
8.3.5  ADVERSE EVENT REPORTING  
 
All a dverse events will be indicated on the data forms for the study and on the specific adverse event report forms and 
all serious adverse events will be reported to the IRB within 24 hours of the research team learning about the event 
followed by a more detail ed written report to the IRB.   The following information about adverse events will be 
collected:   1) the onset and resolution of the event, 2) an assessment of the severity or intensity of the event, 3) an 
assessment of the relationship of the event to the intervention, and 4) any action taken because of event.  The PI [INVESTIGATOR_411615] ( within 7 days ).  
 
8.3.[ADDRESS_519171] include an assessment of 
whether there is a reasonable possibility that the study intervention  caused the event. Study endpoints that are serious 
adverse events (e.g., all -cause mortality) must be reported in accordance with the protocol unless there is evidence 
suggesting a causal relationship between  the study intervention  and the event (e.g., death from anaphylaxis). In that 
case, the investigator must immediately report the event to the sponsor . All serious adverse events ( SAEs ) will be 
followed until satisfactory resolution or until the site investigator deems the event to be chronic or the participant is 
stable.  
 
8.3.[ADDRESS_519172]  
 
Not applicable  
 
8.3.9  REPORTING OF PREGNANCY  
 
Not applicable  
 
8.4 UNANTICIPATED PROBLEMS  
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to participant s or 
others to include, in general, any incident, experience, or outcome that meets all the following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in 
the protocol -related documents, such as the Institutional Review Board ( IRB)-approved research protocol and 
informed consent document; and (b) the characteristics of the participant  population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable 
possibility that the incident, experience, or outcome may have been caused by [CONTACT_32015]); and  
• Suggests that the research places participant s or others at a greater risk of harm (including physical, 
psychological, economic, or social harm) than was previously known or recognized.  
 
 
8.4.2   UNANTICIPATED PROBLEM REPORTING  
 
The investigator  will report unanticipated problems ( UPs) to the reviewing Institutional Review Board ( IRB) and t o the 
principal investigator ( PI). The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in 
response to the UP. 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519173]. Matthew Warner   CONFIDENTIAL  
  
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
 
• UPs that are serious adverse events ( SAEs) will be reported to the IRB within 7-days  of the investigator becoming 
aware of the event.  
• Any other UP will be reported to the IRB and to the DCC/study sponsor within 10-days  of the investigator 
becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written reporting 
procedures), the supporting agency head (or designee), and the Office for Human Research Protections ( OHRP ) 
within 10 days of the IRB’s receipt of the report of th e problem from the investigator.  
 
 
8.4.[ADDRESS_519174].  
 
9 STATISTICAL CONSIDERATIONS   
 
9.1 STATISTICAL HYPOTHESES  
In this study, we will perform a pi[INVESTIGATOR_411616] a multi -faceted anemia intervention (optimized 
phlebotomy practice, decision support,  targeted pharmacologic anemia treatment) to attenuate anemia development 
and promote functional recovery in the setting of critical illness  
Primary endpoint : To assess the impact of the intervention on [ADDRESS_519175] -hospi[INVESTIGATOR_411617].  
Secondary endpoint : To assess the impact of the intervention on post -hospi[INVESTIGATOR_411618] 3 months.  
Hypotheses : A multifaceted anemia intervention will increase hemoglobin concentrations and will improve functional 
recovery through 3 months after hospi[INVESTIGATOR_059].  
 
9.2 SAMPLE SIZE  DETERMINATION  
Power/sample size are calculated to detect a difference in the primary endpoint of hemoglobin at 1 month  follow -up. 
Preliminary data show mean (standard deviation) hemoglobin levels of 10. 8 (1.5) g/dL at [ADDRESS_519176] s 
with similar inclusion/exclusion criteria receiving standard care. A total sample size of 74 (37 per group) provides 80% 
power to detect 1.0 g/dL improvement using a two-sample unequal variances t -test with 2 -sided alpha of 0.05  to 
compare 1 month hemoglobin between randomized arms.  Actual power is expected to be higher under the analysis 
approach, adjusting for pre -randomization prognostic variables to reduce residual variation. If adjustment variables 
account for 25% of the va riation in 1 month hemoglobin (R2 for relationship between pre -randomization adjustment 
variables and outcome = 0.25), the sample size of 37 per group provides 90% power to detect a 1.0 g/dL improvement 
using analysis of covariance with 2 -sided alpha of 0.05. While the analysis uses a lin ear mixed -effects model (LMM), 
power is not appreciably different for the LMM as compared to the unequal variances t -test or ANCOVA described here. 
Given expected dropout of up to 25% (death, loss to follow -up) resulting in loss of information , [ADDRESS_519177]. Matthew Warner   CONFIDENTIAL  
  
As the primary approach, subjects will be analyzed using an intention -to-treat (ITT) approach. Secondarily, analysis will 
be performed using modified intention -to-treat.  
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
Baseline demographic and clinical characteristics will be presented using descriptive statistics, as applicable. Unadjusted 
outcome  summary statistics  will be described for  each randomized  group.   Continuous variables will be summarized by 
[CONTACT_8477] (standard deviation), median (25th, 75th) percentiles, and range .  Categorical variables will be summarized by 
[CONTACT_150780].  
 
The primary analysis dataset consists of all randomized participants and will be analyzed using intention -to-treat (ITT) 
principles such that each subject is analyzed based on their allocated arm.  Mortality and dropout may occur, and 
subjects will be analyzed as described in 9.4.2 and 9.4.3.  
A secondary analysis approach may consider a per -protocol analysis, analyzing those participants who completed study 
procedures without major protocol violations.  The per -protocol analysis definition will be finalized prior to database 
lock and data analy sis.  The ITT analysis will be considered primary.  
 
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
The primary outcome is hemoglobin measured repeatedly on subjects at ICU discharge, hospi[INVESTIGATOR_2345], and [ADDRESS_519178] on 1 month  hemoglobin is the primary outcome; other time -points will reflect secondary outcomes. As 
the functional form of hemoglobin over time is un known, a discrete time representation will be used. The model will 
adjust for pre -randomization hemoglobin, age, sex, anemia etiology, and medical vs surgical ICU setting to reduce 
residual variation and improve precision of the estimated treatment effect.   
Dropout or non -response including skipped study visit and death represent two forms of missing data.  Dropout or non -
response unrelated to death at ICU discharge and hospi[INVESTIGATOR_411619] .  We assume dropout (unrelated to death) while in the ICU is missing completely at random 
(MCAR); subjects withdrawing consent prior to observation of hemoglobin outcome at ICU discharge will be excluded 
from the analysis.  Those droppi[INVESTIGATOR_411620] (MAR) with missingness 
possibly related to adjustment covariates, arm, or prior observed hemoglobin values.  Analyses using LMM assume 
dropout, nonresponse, or skipped visits are MAR.  
We anticipate up to 10% ICU mortality (despi[INVESTIGATOR_411606]) ; such subjects 
will not have observed hemoglobin outcomes. We also anticipate additional post -ICU discharge mortality. In the primary 
analysis, we assume missing data due to death is MAR.  Those with ICU mortality will have ICU discharge hemoglobin 
multiply imputed under the MAR assumption.  Thereafter, LMMs assum e additional missing data at other times are 
MAR.  In secondary approaches to the analysis  of hemoglobin, we use a worst -case imputation approach, to impute 
hemoglobins as the worst possible outcome following death.  After imputation, if residuals are not reasonably normally 
distributed, a generalized linear mixed effects proportional odds mode l will be used or individual timepoints may be 
assessed by [CONTACT_80094] -sum test without covariate adjustment.   
In the primary analysis, the point estimate, 95% confidence interval, and p -value will be reported from the LMM for the 
[ADDRESS_519179]. Matthew Warner   CONFIDENTIAL  
 and two -sided p -value<0.[ADDRESS_519180] the null hypothesis of no treatment benefit in favor of the conclusion that 
intervention improves 1 month hemoglobin.  
 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S)  
 
Secondary and exploratory endpoints (besides hemoglobin at 3 months) include EQ-5D [Time frame: hospi[INVESTIGATOR_2345], 
[ADDRESS_519181] -hospi[INVESTIGATOR_059]] , PROMIS -Fatigue [Time frame: hospi[INVESTIGATOR_2345], [ADDRESS_519182] -hospi[INVESTIGATOR_059]] , 6-minute walk distance , activity monitoring (i.e. daily step counts, daily energy expenditure),  and 
activities of daily living survey [Time frame: [ADDRESS_519183] -hospi[INVESTIGATOR_059]], MoCA -BLIND [Time frame: [ADDRESS_519184] -hospi[INVESTIGATOR_059]], HADS and IES -R [Time frame: [ADDRESS_519185] -hospi[INVESTIGATOR_059]].   
Activity Monitoring:  During the initial consent process for the study, subjects will be given the option to also consent for 
activity monitoring at [ADDRESS_519186] -hospi[INVESTIGATOR_059].  Activity monitors  (AMs) are wearable devices (Actigraph) 
that will be provided  to participants by [CONTACT_2319]. Participants will be asked to wear these  monitors t o measure physical 
activity and sedentary behavior in the free -living environment. The monitors will be worn over 4 consecutive  days, which 
will occur during the  1- and 3 -month assessment  intervals.   Devices will be distributed to patients either in -person 
during their 1 - and 3 -month appointments or delivered via mail.  Participants will be given a pre -paid envelope to mail 
the activity monitors back after  4 consecutive days of wear. A valid A M hour is defined as ≤30 minutes of consecutive 
‘zero’ values (no activity) and a valid AM day is defined as ≥10 wear hours per day. Subjects will be asked to repeat 
wearing the AM if a data collection contains ≤ [ADDRESS_519187] . All activity monitors can be worn comfortably under or over 
clothing. The activity monitors are to be put on in the morning upon waking and removed at night before bed.  The 
sensors are not waterproof and will be removed for bathing and swimming. The risks from wearing an AM are no 
different than those normally encountered in the free -living environment.   Instructions for participants are provided in 
Appendix 3.  
Analyses will use Wilcoxon rank -sum tests to compare the distribution of each outcome between groups at each 
timepoint since assumptions including normality of residuals are not expected to be satisfied for these outcomes.  
Additional, when applicable , a cutpoint defining a clinically actionable adverse outcome may be defined, for example, 
defining depression by [CONTACT_265134] -Depression ≥8.  Binary outcomes will be summarized as proportion and compared by  
[CONTACT_411660] a  Chi-square test.   Death and dropout wi ll be assumed MAR in the primary approach and multiple 
imputation will be used to impute missing values.  Analyses will be conducted on each imputed dataset and results 
combined to reflect uncertainty due to missing data.  An additional analysis will consi der a worst -value imputation for 
mortality, assigning death the worst possible outcome.  
Mortality and readmission through [ADDRESS_519188] with the Mayo medical system when status is unknown at 
1 year.  Inferential analyses will use log -rank tests and Gray’s test for mortality and readmission outcomes, respectively.  
 
Since the goal is to provide robust data for further clinical trial evaluation, secondary and exploratory outcomes will be 
assessed without adjustment for multiplicity, with conclusions from each based on a two -sided alpha level 0.[ADDRESS_519189] been planned as outlined throughout the protocol.  These will be utilized to inform a 
definitive multicenter phase III clinical trial.   
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PROCESS  
 
[IP_ADDRESS]  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS  
 
Consent forms describing in detail the study intervention , study procedures, and risks are given to the participant  and 
written documentation of informed consent is required prior to starting intervention/administering study intervention .  
The following consent materials are submitted with this protocol : Consent form.  
 
[IP_ADDRESS]  CONSENT PROCEDURES AND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues 
throughout the individual’s study participation.  Consent forms will be Institutional Review Board ( IRB)-approved and the 
participant /LAR  will be asked to read and review the document. The study coordinator will explain the research study to 
the participant  &/or LAR  and answer any questions that may arise. A verbal explanation will be provided in terms suited 
to the  participant’s compr ehension of the purposes, procedures, and potential risks of the study and of their rights as 
research participants.  Participants /LAR  will have the opportunity to carefully review the written consent form and ask 
questions prior to signing.  The participant s should have the opportunity to discuss the study with their family or 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519190]. Matthew Warner   CONFIDENTIAL  
 surrogates or think about it prior to agreeing to participate. The participant /LAR  will sign the informed consent 
document prior to any procedures being done specifically for the study.  Participant s must be informed that participation 
is voluntary and that they may withdraw from the study at any time, without prejudice.  A copy of the informed consent 
document will be given to the participant s for their records. The informed consent process will be conducted and  
documented in the source document (including the date), and the form signed, before the participan t undergoes any 
study -specific procedures.  The rights and welfare of the participant s will be protected by [CONTACT_142321].  
10.1.2  STUDY DISCONTINUATION AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause.  Written 
notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_411661], investigator, funding agency , and regulatory authorities.  If the study is 
prematurely terminated or suspended, the  PI [INVESTIGATOR_112578], IRB, and sponsor and will provide 
the reason(s) for the termination or suspension.  Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of 
changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that  the primary endpoint has been met  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed , and satisfy the 
sponsor, IRB and/or Food and Drug Administration ( FDA). 
 
10.1.[ADDRESS_519191] by [CONTACT_3486], their staff, and the 
sponsor(s) and their intervention s. This confidentiality is extended to cover testing of biological samples and genetic 
tests in addition to the clinical information relating to participa nts. Therefore, the study protocol, documentation, data, 
and all other information generated will be held in strict confidence. No information concerning the study or the data 
will be released to any unauthorized third party without prior written approval of the sponsor.  
 
All research activities will be conducted in as private a setting as possible.  
 
The study monitor, other authorized representatives of the sponsor, representative s of the I RB, regulatory agencies  or 
pharmaceutical company supplying study product may inspect all documents and records required to be maintained by 
[CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the 
participant s in this study. The clinical study site will permit access to such records.  
 
The study participant’s contact [CONTACT_10414]. 
At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_373319], Institutional policies, or sponsor requirements . 
 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519192]. Matthew Warner   CONFIDENTIAL  
 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted 
to and stored at the Mayo Clinic. This will not include the participant’s contact [CONTACT_1290]. Rather, 
individual participants and their research data will be identified by a unique study identification number. The study data 
entry and study management systems will be secured,  and password protected. At the end of the study, all study 
databases will be de -identified and  archived at the Mayo Clinic.  
 
Certificate of Confidentiality  
To further protect the privacy of study participant s, a Certificate of Confidentiality will be issued  by [CONTACT_66121] ( NIH).  This certificate protects identifiable research information from forced disclosure. It allows the 
investigator and others who have access to research records to refuse to disclose identifying information on research 
participation in any civil, criminal,  administrative, legislative, or other proceeding, whether at the federal, state, or local 
level. By [CONTACT_411662] s, Certificates of Confidentia lity help achieve the research objectives and promote participation in 
studies by [CONTACT_4205][INVESTIGATOR_411621].  
 
 
10.1.4  FUTURE USE OF STORED SPECIMENS  AND DATA   
 
With the participant’s approval and as approved by [CONTACT_50810], de -identified biological samples will be stored at the 
Mayo Clinic  with the same goal as the sharing of data with the  Mayo Clinic . These samples could be used to research the 
causes of anemia,  its complications and other conditions f or which individuals with  anemia are at increased risk, and to 
improve treatment. The PI [INVESTIGATOR_411622] a record that will allow linking the biological specimens with the 
phenotypic data from each participant, maintaining the blind ing of the identity of the participant.  
 
During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens 
stored for future research. However, withdrawal of consent with regard to biosample storage may  not be possible after 
the study is completed.  
 
When the study is  completed , access to study data and/or samples will be provided through the PI [INVESTIGATOR_411623].  
 
10.1.5  KEY ROLES  AND STUDY GOVERNANCE  
 
Principal Investigator  
[INVESTIGATOR_40613] A. Warner, MD, Associate Professor of Anesthesiology  
Mayo Clinic  
 
 
 
 
10.1.6  SAFETY OVERSIGHT  
 
Safety oversight will be conducted in accordance with the Data and Safety Monitoring Plan (DSMP) .  
 
10.1.[ADDRESS_519193]. Matthew Warner   CONFIDENTIAL  
 currently approved protocol/amendment(s), with International Conference on Harmonisation Good Clinical Practice ( ICH 
GCP), and with applicable regulatory requirement(s).  
 
It is the responsibility of the Principal Investigator [INVESTIGATOR_133605].  This safety monitoring will inclu de 
careful assessment and appropriate reporting of adverse events as noted above, as well as the construction and 
implementation of  a site data and safety -monitoring plan .  Medical monitoring will include a regular assessment of the 
number and type of serious adverse events  
 
10.1.[ADDRESS_519194], data and biological specimen  collection, 
documentation and completion.  An individualized quality management plan will be developed to describe a site’s 
quality management.  
 
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC checks that will 
be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s)  for 
clarification/resolution.  
 
Following written Standard Operating Procedures ( SOPs ), the monitors will verify that the clinical trial is conducted and 
data are generated  and biological specimens are collected , documented (recorded), and reported in compliance with 
the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory 
requirements (e.g., Good Laboratory Practices ( GLP), Good Manufacturing Practices ( GMP )).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the 
purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_9177].  
 
 
10.1.[ADDRESS_519195]  KEEPI[INVESTIGATOR_1645]   
 
[IP_ADDRESS]  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site investigator . The 
investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported .  All 
source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  Hardc opi[INVESTIGATOR_411624].  Data collected and entered into electronic case report form ( eCRF ) derived from 
source documents should be consistent with the data recorded on the source documents . Clinical data (including 
adverse events ( AEs), concomitant medications, and expected adverse reactions data) and clinical laboratory data will be 
entered into REDCap electronic data capture . REDCap is HIPAA -compliant with built -in user right controls and audit trails 
for data security and tracking.  The data system includes password protection and internal quality checks, such as 
automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be 
entered directly from the source documents.  
 
[IP_ADDRESS]  STUDY RECORDS RETENTION  
 
Study documents should be retained for a minimum of [ADDRESS_519196]. Matthew Warner   CONFIDENTIAL  
  
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on Harmonisation 
Good Clinical Practice ( ICH GCP) , or Manual of Procedures ( MOP) requirements. The noncompliance may be either on 
the part of the participant , the investigator, or the study site staff. As a result of deviations, corrective actions are to be 
developed by [CONTACT_3483].  
 
These practices are consistent with ICH GCP:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_519197] (IRB)  per their policies . The site investigator  is responsible for knowing and 
adhering to the  reviewing IRB requirements.  
 
10.1.11  PUBLICATION AND DATA SHARING POLICY  
 
This study will  be conducted in accordance with the following  publication and data sharing  policies and regulations:  
 
National Institutes of Health ( NIH) Public Access Policy , which ensures that the public has access to the published results 
of NIH funded research. It requires scientists to submit final peer -reviewed journal manuscripts that arise from NIH 
funds to the digital archive PubMed Central  upon acceptance for publication.  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded Clinical Trial 
Information and the Clinical Trials Registration and Results Information Submission r ule. As such,  this trial will be  
registered at ClinicalTrials.gov , and results information  from this  trial will be submitted to ClinicalTrials.gov.  In addition, 
every attempt will be made to publish results in peer -reviewed journals.  Data from this study may be request ed from 
other researchers within [ADDRESS_519198].  
 
 
 
10.2 ADDITIONAL CONSIDERATIONS  
 
Appendix 1: Visual Aid  
 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519199]. Matthew Warner   CONFIDENTIAL  
  
 
 
 
 Appendix  2: Daily Rounding  

 
Protocol PABST -BR                             Version 5.[ADDRESS_519200]  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation   
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ISM Independent Safety Monitor  
ISO International Organization for Standardization  
ITT Intention -To-Treat  
IV Intravenous  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NCT National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
PI [INVESTIGATOR_411625] -BR                             Version 5.[ADDRESS_519201]. Matthew Warner   CONFIDENTIAL  
 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a description of the 
change and rationale. A Summary of Changes table for the current amendment is located in the Protocol Title Page.  
 
Version  Date  Description of Change   Brief Rationale  
2 March 28, 
2022  Revision of inclusion/exclusion 
criteria  Improve clarity of inclusion and exclusion items.  
[ADDRESS_519202]. Matthew Warner   CONFIDENTIAL  
 11 REFERENCES  
 
1.  Walsh TS, Saleh E -E-D. Anaemia during critical illness. Br J Anaesth . 2006;97(3):278 -291. doi:10.1093/bja/ael189  
2.  Thomas J, Jensen L, Nahirniak S, Gibney RTN. Anemia and blood transfusion practices in the critically ill: A 
prospective cohort review. Hear Lung J Acute Crit Care . 2010;39(3):217 -225. doi:10.1016/j.hrtlng.2009.07.[ADDRESS_519203], et al. Prevalence and Recovery from Anemia Following Hospi[INVESTIGATOR_411626], 2010 -2016. JAMA Netw Open . 2020;[Accepted.  
4.  Hébert PC, Wells G, Blajchman MA, et al. A Multicenter, Randomized, Controlled Clinical Trial of Transfusion 
Requirements in Critical Care. N Engl J Med . 1999;340(6):409 -417. doi:10.1056/NEJM199902113400601  
5.  Needham DM, Davidson J, Cohen H, et al. Improving long -term outcomes after discharge from intensive care 
unit. Crit Care Med . 2012;40(2):502 -509. doi:10.1097/CCM.0b013e318232da75  
6.  Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID -19) 
Outbreak in China: Summary of a Report of [ZIP_CODE] Cases from the Chinese Center for Disease Control and 
Prevention. JAMA - J Am Med Assoc . 2020;323(13):1239 -1242. doi:10.1001/jama.2020.[ADDRESS_519204], et al. Anemia in Critically Ill Patients With Acute Respi[INVESTIGATOR_411627]. J Intensive Care Med . 1(9). doi:10.1177/[ADDRESS_519205] of anemia and 
comorbidity on functional status and mortality in old age: Results from the Leiden 85 -plus Study. Cmaj . 
2009;181(3 -4):151 -157. doi:10.1503/cmaj.[ADDRESS_519206] of anemia on mortality, cognition, and function in community -
dwelling elderly. Am J Med . 2006;119(4):327 -334. doi:10.1016/j.amjmed.2005.08.027  
10.  Bandinelli S, Ferrucci L, Corsi AM, et al. Anemia Is Associated with Disability and Decreased Physical Performance 
and Muscle Strength in the Elderly. J Am Geriatr Soc . 2004;52(5):719 -724. doi:10.1111/j.1532 -5415.2004.[ZIP_CODE].x  
11.  Thein M, Ershler WB, Artz AS, et al. Diminished quality of life and physical function in community -dwelling elderly 
with anemia. Medicine (Baltimore) . 2009;88(2):107 -114. doi:10.1097/MD.0b013e31819d89d5  
12.  Conlon NP, Bale EP, Herbison GP, McCarroll M. Postoperative Anemia and Quality of Life After Primary Hip 
Arthroplasty in Patients Over 65 Years Old. Anesth Analg . 2008;106(4):1056 -1061. 
doi:10.1213/ane.0b013e318164f114  
13.  Lawrence VA, Silverstein JH, Cornell JE, Pederson T, Noveck H, Carson JL. Higher Hb level is associated with better 
early functional recovery after hip fracture repair. Transfusion . 2003;43(12):1717 -1722. doi:10.1046/j.0041 -
1132.2003.[ZIP_CODE].x  
14.  Foss NB, Kristensen MT, Kehlet H. Anaemia impedes functional mobility after hip fracture surgery. Age Ageing . 
2008;37(2):173 -178. doi:10.1093/ageing/afm161  
15.  Fukushima T, Nakano J, Ishii S, et al. Influence of Hemoglobin Level on Muscle and Physical Functions, Activities of 
Daily Living, and Quality of Life in Patients With Hematological Malignancies. Integr Cancer Ther . 2019;18:1 -7. 
doi:10.1177/1534735419842196  
16.  Morishita S, Kaida K, Yamauchi S, et al. Relationship between corticosteroid dose and declines in physical 
function among allogeneic hematopoietic stem cell transplantation patients. Support Care Cancer . 
2013;21(8):2161 -2169. doi:10.1007/s00520 -013-1778 -7 
17.  Peuranp € A € A P, Heli S, Ovaara -Peippo €, Fraser I, Paavonen J, Ritva Hurskainen &. Effects of anemia and iron 
deficiency on quality of life in women with heavy menstrual bleeding. doi:10.1111/aogs.[ZIP_CODE]  
18.  Roubinian NH, Murphy EL, Mark DG, et al. Long -Term Outcomes Among Patients Discharged From the Hospi[INVESTIGATOR_411628]. Ann Intern Med . 2019;170(2):81. doi:10.7326/M17 -[ADDRESS_519207] practice in critical care: anaemia in acute and critical illness. Transfus 
Med . 2018;28(2):181 -189. doi:10.1111/tme.[ZIP_CODE]  
20.  Bateman AP, McArdle F, Walsh TS. Time course of anemia during six months follow up following intensive care 
discharge and factors associated with impaired recovery of erythropoiesis. Crit Care Med . 2009;37(6):1906 -1912. 
doi:10.1097/CCM.0b013e3181a000cf  
21.  St Sauver JL, Grossardt BR, Finney Rutten LJ, et al. [COMPANY_002]ster Epi[INVESTIGATOR_411629]. Prev 
 
Protocol PABST -BR                             Version 5.[ADDRESS_519208]. Matthew Warner   CONFIDENTIAL  
 Chronic Dis . 2018;15:E42. doi:10.5888/pcd15.[ADDRESS_519209]: Half a 
Century of Medical Records Linkage in a US Population. Mayo Clin Proc . 2012;87(12):1202 -1213. 
doi:10.1016/J.MAYOCP.2012.08.012  
23.  Needham DM, Sepulveda KA, Dinglas VD, et al. Core outcome measures for clinical research in acute respi[INVESTIGATOR_411630]. Am J Respir Crit Care Med . 2017;196(9):1122 -
1130. doi:10.1164/rccm.201702 -0372OC  
24.  Wu Y, Spaulding AC, Borkar S, et al. Reducing Blood Loss by [CONTACT_411663]. Mayo Clin Proc Innov Qual Outcomes . 2021;5(1):72 -83. doi:10.1016/J.MAYOCPI[INVESTIGATOR_411631].2020.08.007  
25.  Siegal DM, Belley -Cote E, Arnold DM, et al. Small -Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A 
Pragmatic Stepped Wedge Cluster Randomized Trial. Blood . 2019;134(Supplement_1):3685 -3685. 
doi:10.1182/BLOOD -2019 -130257  
26.  Barreda Garcia J, Xian JZ, Pedroza C, et al. Pediatric size phlebotomy tubes and transfusions in adult critically ill 
patients: A pi[INVESTIGATOR_2269]. Pi[INVESTIGATOR_182240] . 2020;6(1):1 -9. doi:10.1186/s40814 -020-[ZIP_CODE] -
3 
27.  Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients. 
JAMA . 2002;288(22):2827. doi:10.1001/jama.288.22.2827  
28.  Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and Safety of Epoetin Alfa in Critically Ill Patients. N Engl J Med . 
2007;357(10):965 -976. doi:10.1056/NEJMoa071533  
29.  Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of Recombinant Human Erythropoietin in the Critically Ill 
Patient. Crit Care Med . 1998;26(Supplement):23A. doi:10.1097/00003246 -199801001 -[ZIP_CODE]  
30.  Shah A, Fisher SA, Wong H, et al. Safety and efficacy of iron therapy on reducing red blood cell transfusion 
requirements and treating anaemia in critically ill adults: A systematic review with meta -analysis and trial 
sequential analysis. J Crit Care . 2019;49:162 -171. doi:10.1016/j.jcrc.2018.11.[ADDRESS_519210] care: a multicenter, randomized, 
single -blinded trial. Crit Care . 2021;25(1):1 -10. doi:10.1186/s13054 -020-[ZIP_CODE] -3 
32.  The IRONMAN Investigators, Litton E, Baker S, et al. Intravenous iron or placebo for anaemia in intensive care: 
the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illness. Intensive Care 
Med . 2016;42(11):1715 -1722. doi:10.1007/s00134 -016-4465 -6 
33.  Richards T, Clevenger B, Keidan J, et al. PREVENTT: Preoperative intravenous iron to treat anaemia in major 
surgery: Study protocol for a randomised controlled trial. Trials . 2015;16(1). doi:10.1186/s13063 -015-[ADDRESS_519211] . 2006;21:378 -382. doi:10.1093/ndt/gfi253  
35.  Litton E, Latham P, Inman J, Luo J, Allan P. Safety and efficacy of erythropoiesis -stimulating agents in critically ill 
patients admitted to the intensive care unit: a systematic review and meta -analysis. Intensive Care Med . 
2019;45(9):1190 -1199. doi:10.1007/s00134 -019-[ZIP_CODE] -y 
36.  M H, R L, C R, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: 
randomised, double -blind, placebo -controlled trial. Lancet (London, England) . 2003;362(9392):1255 -1260. 
doi:10.1016/S0140 -6736(03)[ZIP_CODE] -9 
37.  JR W, YC U, JA J, et al. Randomized, double -blind, placebo -controlled trial of erythropoietin in non -small -cell lung 
cancer with disease -related anemia. J Clin Oncol . 2007;25(9):1027 -1032. doi:10.1200/JCO.2006.07.[ADDRESS_519212] -line chemotherapy: a survival study. J Clin Oncol . 2005;23(25):5960 -5972. 
doi:10.1200/JCO.2005.06.150  
39.  Choi MJ, Yee J. Erythropoiesis -Stimulating Agents and Cancer: Myth or Truth. Published online 2019. 
doi:10.1053/j.ackd.2019.04.001  
40.  J B, K B, R C, et al. Management of Cancer -Associated Anemia With Erythropoiesis -Stimulating Agents: ASCO/ASH 
Clinical Practice Guideline Update. J Clin Oncol . 2019;37(15):1336 -1351. doi:10.1200/JCO.18.[ADDRESS_519213]. Matthew Warner   CONFIDENTIAL  
 Published online March 2020:1. doi:10.1213/ANE.0000000000004727  
42.  Litton E, Latham P, Inman J, Luo J, Allan P. Safety and efficacy of erythropoiesis -stimulating agents in critically ill 
patients admitted to the intensive care unit: a systematic review and meta -analysis. Intensive Care Med . 
2019;45(9):1190 -1199. doi:10.1007/s00134 -019-[ADDRESS_519214] of iron deficiency diagnosis using hepcidin mass spectrometry dosage 
methods on hospi[INVESTIGATOR_411632] a prolonged ICU stay: Study protocol for a multicentre, randomised, 
single -blinded medico -economic  trial. Anaesth Crit Care Pain Med . 2017;36(6):391 -396. 
doi:10.1016/j.accpm.2017.04.[ADDRESS_519215] (Larchmt) . 2005;6(s1):s41 -s46. 
doi:10.1089/sur.2005.6.s1 -41 
45.  Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics . 
2011;3(1):12 -33. doi:10.3390/pharmaceutics3010012  
46.  Warner MA, Shore -Lesserson L, Shander A, Patel SY, Perelman SI, Guinn NR. Perioperative Anemia. Anesth Analg . 
Published online March 2020:1. doi:10.1213/ane.[ADDRESS_519216] of ultra -short -term treatment of patients with iron deficiency or 
anaemia undergoing cardiac surgery: a prospective randomised trial. Lancet . 2019;6736(18):1 -12. 
doi:10.1016/S0140 -6736(18)[ADDRESS_519217] 
(Larchmt) . 2009;10(1):9 -19. doi:10.1089/sur.2008.043  
49.  Pi[INVESTIGATOR_411633], Stovall RT, Jaouen B, et al. A multicenter, randomized clinical trial of IV iron supplementation for 
anemia of traumatic critical illness*. Crit Care Med . 2014;42(9):2048 -2057. doi:10.1097/CCM.[ADDRESS_519218], Needham DM. Understanding patient -important outcomes after critical illness. Curr Opin 
Crit Care . 2018;24(5):401 -409. doi:10.1097/MCC.0000000000000533  
51.  Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: Design and sampling, participation, 
baseline measures and sample characteristics. Neuroepi[INVESTIGATOR_623] . 2008;30(1):58 -69. doi:10.1159/000115751  
 